JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

JNJ

227.46

+0.25%↑

ISRG

503.04

-3.51%↓

ABT

105.97

-0.11%↓

MDT

100.49

-0.34%↓

A

132.5

-1.62%↓

Search

IQVIA Holdings Inc

Open

SectorGezondheidszorg

235.84 -1.52

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

232.97

Max

240.01

Belangrijke statistieken

By Trading Economics

Inkomsten

66M

332M

Verkoop

83M

4.1B

K/W

Sectorgemiddelde

32.889

90.422

Winstmarge

8.098

Werknemers

91,000

EBITDA

102M

883M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+8.12% upside

Dividenden

By Dow Jones

Volgende Winsten

5 feb 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

3.3B

41B

Vorige openingsprijs

237.36

Vorige sluitingsprijs

235.84

Nieuwssentiment

By Acuity

50%

50%

133 / 352 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

IQVIA Holdings Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

28 jan 2026, 23:51 UTC

Winsten

Correction to Samsung Fourth-Quarter Net Profit Article

28 jan 2026, 23:49 UTC

Populaire aandelen

Stocks to Watch: Meta, IBM, Las Vegas Sands, Whirlpool

28 jan 2026, 23:19 UTC

Winsten

Samsung's Fourth-Quarter Net Profit Beats Consensus

28 jan 2026, 22:43 UTC

Winsten

Waste Management Logs Higher 4Q Profit as Revenue Rises

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Diller's Overture Came Before Warner Unveiled Split Plans, Source Says -- WSJ

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Warner Says CNN Wasn't and Isn't for Sale -- WSJ

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Barry Diller Told Warner Bros. Discovery He Is Interested in Buying CNN -- WSJ

29 jan 2026, 00:00 UTC

Acquisities, Fusies, Overnames

Barry Diller Approached Warner Bros. Discovery Last Year About Buying CNN, Sources Say -- WSJ

28 jan 2026, 23:49 UTC

Marktinformatie

Nikkei May Rise as Weaker Yen Supports Earnings Hopes -- Market Talk

28 jan 2026, 23:30 UTC

Marktinformatie

Tesla to Use Car Factory for Robot Aims -- Market Talk

28 jan 2026, 23:28 UTC

Winsten

Microsoft's Earnings Surge, Elevated by Cloud Business -- 3rd Update

28 jan 2026, 23:26 UTC

Winsten

Meta Reports Record Sales, Massive Spending Hike on AI Buildout -- 2nd Update

28 jan 2026, 23:21 UTC

Winsten

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 jan 2026, 23:18 UTC

Winsten
Acquisities, Fusies, Overnames

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 jan 2026, 22:58 UTC

Winsten

Tesla to Invest $2 Billion in Elon Musk's xAI -- Update

28 jan 2026, 22:48 UTC

Marktinformatie

Woodside Energy Has Form With Conservative Production Guidance -- Market Talk

28 jan 2026, 22:45 UTC

Winsten

Samsung Electronics 2025 Net KRW45.207T Vs. Net KRW34.451T >005930.SE

28 jan 2026, 22:44 UTC

Winsten

Samsung Electronics 2025 Oper Pft KRW43.601T Vs. Pft KRW32.726T >005930.SE

28 jan 2026, 22:43 UTC

Winsten

Samsung Electronics 2025 Rev KRW333.606T Vs. KRW300.871T >005930.SE

28 jan 2026, 22:41 UTC

Winsten
Populaire aandelen

Earnings in Focus Wednesday: Microsoft, Tesla, Meta, Starbucks -- WSJ

28 jan 2026, 22:41 UTC

Marktinformatie

Rising AUD Typically Sees Australian Stocks Outperform -- Market Talk

28 jan 2026, 22:41 UTC

Winsten

Meta Stock Rises on Strong Earnings. Expenses Are Mounting. -- Barrons.com

28 jan 2026, 22:40 UTC

Winsten

Samsung Electronics 4Q Net Profit Beat FactSet-Compiled Consensus

28 jan 2026, 22:39 UTC

Winsten

Samsung Electronics 4Q Net KRW19.642T Vs. Net KRW7.754T >005930.SE

28 jan 2026, 22:38 UTC

Winsten

Samsung Electronics 4Q Oper Pft KRW20.074T Vs. Pft KRW6.493T >005930.SE

28 jan 2026, 22:37 UTC

Winsten

Samsung Electronics 4Q Rev KRW93.837T Vs. KRW75.788T >005930.SE

28 jan 2026, 22:35 UTC

Winsten

Microsoft Stock Falls Despite Earnings Beat. Cloud Growth Slowed Slightly. -- Barrons.com

28 jan 2026, 22:26 UTC

Marktinformatie
Winsten

Meta's Rising CapEx is Fueled by High Pay for AI Workers -- Market Talk

28 jan 2026, 22:20 UTC

Marktinformatie

Global Equities Roundup: Market Talk

28 jan 2026, 22:20 UTC

Marktinformatie

Woodside Energy's Oil Assets Blamed for Guidance Miss -- Market Talk

Peer Vergelijking

Prijswijziging

IQVIA Holdings Inc Prognose

Koersdoel

By TipRanks

8.12% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 260.62 USD  8.12%

Hoogste 290 USD

Laagste 230 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor IQVIA Holdings Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

14 ratings

11

Buy

3

Hold

0

Sell

Technische score

By Trading Central

150.68 / 153.45Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Neutral Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

133 / 352 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat